Bruker Corporation (BRKR) recently entered into a definitive agreement to acquire a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions, Chemspeed Technologies AG. This marks a significant stride into the realm of lab automation, digitalization, and scientific software solutions.This strategic move positions Bruker to further strengthen its Project Accelerate 2.0 initiative, which is focused on “Assays, Software, and Aftermarket.”Accelerating Entry Into AutomationChemspeed T ...

BASEL, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG, a Swiss provider of vendor-agnostic automated laboratory R&D and QC workflow solutions. Chemspeed is focused on modular automation and robotics solutions for chemical research, pharma drug formulation, materials research for cleantech and consumer applications. The Chemspeed acquisition accelerates Bruker’s entry into lab automation, digitalizatio ...

ZURICH & NEWTON, Massachusetts--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers. The Massachusetts facility will initially focus on TrueDiscovery® data-independent acquisition (DIA) discovery proteomics services that o ...

Bruker Corporation (BRKR) is likely to grow in the coming quarters due to the solid prospects of the Bruker Scientific Instruments (“BSI”) Nano and BioSpin group. The addition of PhenomeX complements the Bruker cellular and sub-cellular analysis tools and brings opportunities for commercial synergies.However, BRKR’s operations are subject to intense competition from its peers in the industry.In the past year, this Zacks Rank #3 (Hold) stock has increased 5% against the 14.2% fall of the industry and a 22.6% ...

Bruker Corporation (NASDAQ:BRKR) 42nd Annual J.P. Morgan Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Frank Laukien - President and Chief Executive Officer Gerald Herman - Executive Vice President and Chief Financial Officer Mark Munch - President, Bruker Nano Group and Corporate Executive Vice President Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal This is Rachel Vatnsdal from the life science tools and diagnostics team at JPMorgan. Pleased to introduce ...

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY (in millions, except share data) | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------|-------|-------------------------|----------------------|------------| | Cash flows from operating activities: | | Nine September \n2023 | Months Ended 30, | 2022 | | Consolidated net income | $ | 223.9 | $ | 200.2 | | Adjus ...

(1)All in constant currency, and in comparison to the nine months ended September 30, 2022 Q3 2023 Earnings Presentation November 2, 2023 Introducing Bruker Cellular Analysis, a Leader in Single-Cell Biology Tools Complements Bruker's spatial biology and single-cell research tools via acquisition of PhenomeX Beacon® Optofluidic Systems (former Berkeley Lights) IsoSpark® System (former IsoPlexis) Strategic Rationale ✓ Technologies unique, highly valued by customers ✓ Expands footprint in translational, clini ...

Bruker Corporation (NASDAQ:BRKR) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Mark Munch - President, Bruker Nano Group and Corporate Executive Vice President Derik De Bruin - Bank of America Rachel Vatnsdal - JPMorgan Greetings, ladies and gentlemen. Thank you for attending todayÂ's conference call. I would now like to turn the call over to Justin Ward, Head of Investor Relations. Please go ahead. Before we begin, I would like to reference BrukerÂ's Safe Harbor statement, which is shown on ...

Bruker Corporation (NASDAQ:BRKR) Morgan Stanley 21st Annual Global Healthcare Conference Call September 13, 2023 4:14 PM ET Company Participants Gerald Herman - Executive Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant All right. Good afternoon, everyone. I’m Tejas Savant, and I’m the life sciences analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at mo ...

17. Business Segment Information | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------|-----------------|-----------------------------------------|---------------------------|--------------|-------|-----------------------|--------------|------------| | Operating income by reportable segment | are presented | below (in \nThree Months \n2023 | millions): \nEnded June | 30, \n2022 | | Six Months \n2023 | Ended June | 30, \n2022 | | Operating income (loss): | ...